ThirtyFiveBio Closes Bridge Round of Financing Highlighted by Strategic New Investment from AbbVie Ventures
ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced the closing of a...